Radium-223

DRUG19 trials

Sponsors

Yoshida Soichiro, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MedSIR

Conditions

Advanced CancerBiochemical Recurrent Prostate CancerBone MetastasesCastrate Resistant Prostate CancerCastration-Resistant Prostate CarcinomaCastration-resistantMCRPCMetastatic Castration Resistant Prostate Cancer (mCRPC)

Early Phase 1

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

TerminatedNCT03208712

University of Michigan Rogel Cancer CenterUrothelial Carcinoma

Start: 2017-11-01End: 2018-08-02Updated: 2018-10-24

Phase 1

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

CompletedNCT02406521

Dana-Farber Cancer InstituteMetastatic Renal Cell Carcinoma

Start: 2015-04-30End: 2019-12-31Updated: 2020-03-04

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

Active, not recruitingNCT04109729

University of UtahMetastatic Castration-resistant Prostate Cancer

Start: 2020-09-16End: 2026-04-30Target: 39Updated: 2026-03-02

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingNCT05383079

Peter MacCallum Cancer Centre, AustraliaMCRPC, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer

Start: 2022-09-13End: 2026-12-01Target: 36Updated: 2025-02-07

Phase 2

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

CompletedNCT02278055

Memorial Sloan Kettering Cancer CenterMetastatic Prostate Cancer, Pain

Start: 2014-10-08End: 2022-02-02Updated: 2023-04-07

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

CompletedNCT02463799

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer

Start: 2016-02-22End: 2019-12-12Updated: 2021-07-08

Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

CompletedNCT03002220

MedSIRProstate Cancer

Start: 2016-12-21End: 2021-06-09Updated: 2024-12-11

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

CompletedNCT03093428

Dana-Farber Cancer InstituteProstate Cancer

Start: 2017-06-09End: 2025-02-28Updated: 2025-03-28

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Active, not recruitingNCT03230734

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSMetastatic Castration-resistant Prostate Cancer

Start: 2017-09-01End: 2025-07-31Target: 70Updated: 2024-09-27

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

CompletedNCT04037358

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer

Start: 2019-08-09End: 2025-07-15Updated: 2025-12-19

Radium-223 in Biochemically Recurrent Prostate Cancer

Active, not recruitingNCT04206319

National Cancer Institute (NCI)Biochemical Recurrent Prostate Cancer

Start: 2020-09-22End: 2026-07-31Updated: 2026-03-16

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

RecruitingNCT04704505

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsCastration-resistant, Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma

Start: 2022-04-28End: 2029-02-01Target: 47Updated: 2026-02-06

MEtastasis-Directed therapy with Alpha emitter Radium-223 for Oligometastatic Castration-resistant prostate cancer

Active, not recruitingJPRN-jRCTs031200358

Yoshida SoichiroProstatic Neoplasms, Castration-Resistant

Start: 2021-03-29Target: 44Updated: 2025-07-18

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Active, not recruitingNCT05924672

University of California, San FranciscoCastration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IVB Prostate Cancer AJCC v8

Start: 2024-08-30End: 2027-03-31Updated: 2026-01-14

Phase 3

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Active, not recruitingNCT03574571

Memorial Sloan Kettering Cancer CenterProstate Cancer

Start: 2018-06-19End: 2027-04-01Updated: 2026-02-27

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

WithdrawnNCT05771896

GenesisCare USAMetastatic Prostate Cancer

Start: 2023-09-30End: 2029-04-30Updated: 2023-09-14

Unknown Phase

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

CompletedNCT04995614

Radboud University Medical CenterBone Metastases, Castrate Resistant Prostate Cancer

Start: 2017-04-01End: 2020-06-29Updated: 2021-08-09

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

CompletedNCT05701007

PfizerMetastatic Castration Resistant Prostate Cancer (mCRPC), Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Start: 2023-02-13End: 2024-04-10Updated: 2026-01-29

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

RecruitingNCT06389097

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAdvanced Cancer, Prostate Cancer

Start: 2025-02-03End: 2029-08-01Target: 80Updated: 2026-03-30

Related Papers

Lutetium-177 [<sup>177</sup>Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

2025-10-181 citations

Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.

Journal of Clinical Oncology2025-02-10

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone.

2024-11-201 citations

The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of<sup>223</sup>Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

Journal of Nuclear Medicine2024-02-293 citations

Abstract 5043: Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer

Cancer Research2023-04-042 citations

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).

2023-03-064 citations

AlphaBet: A phase I/II trial evaluating the combination of radium-223 and [<sup>177</sup>Lu]Lu-PSMA-I&T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2023-02-202 citations

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in Medicine2022-11-1840 citations

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.

2022-08-167 citations

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Prostate Cancer and Prostatic Diseases2022-07-0813 citations

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Journal of Clinical Oncology2021-05-206 citations

Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2021-02-2014 citations

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer2020-06-0132 citations

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Journal of Clinical Oncology2020-05-201 citations

A phase II randomized trial of RAdium-223 dichloride and SABR versus SABR for oligomEtastatic prostate caNcerS (RAVENS).

Journal of Clinical Oncology2020-05-201 citations

Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer.

Journal of Clinical Oncology2020-05-20

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

JAMA Oncology2020-03-261068 citations

Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-02-198 citations

Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response.

Journal of Clinical Oncology2020-02-191 citations

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

European Journal of Cancer2019-05-1154 citations

4 more papers not shown